Total Payments
$2.4M
2024 Payments
$761,784
Companies
45
Transactions
3,175
Medicare Patients
4,929
Medicare Billing
$426,209
Payment Breakdown by Category
Other$1.8M (77.2%)
Consulting$255,476 (10.7%)
Travel$220,317 (9.2%)
Food & Beverage$61,049 (2.6%)
Research$7,568 (0.3%)
Education$765.92 (0.0%)
Gifts$25.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 767 | 76.6% |
| Consulting Fee | $255,476 | 84 | 10.7% |
| Travel and Lodging | $220,317 | 648 | 9.2% |
| Food and Beverage | $61,049 | 1,622 | 2.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $12,120 | 7 | 0.5% |
| Unspecified | $7,568 | 2 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,900 | 2 | 0.1% |
| Education | $765.92 | 15 | 0.0% |
| Gift | $25.76 | 28 | 0.0% |
Payments by Type
General
$2.4M
3,173 transactions
Research
$7,568
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $582,245 | 530 | $0 (2024) |
| Lilly USA, LLC | $500,190 | 811 | $0 (2024) |
| Dermavant Sciences, Inc. | $279,206 | 219 | $0 (2024) |
| Janssen Biotech, Inc. | $227,743 | 280 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $162,487 | 146 | $0 (2024) |
| Amgen Inc. | $157,364 | 141 | $0 (2024) |
| UCB, Inc. | $150,035 | 152 | $0 (2024) |
| Galderma Laboratories, L.P. | $86,060 | 230 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $81,560 | 67 | $0 (2024) |
| PFIZER INC. | $43,296 | 73 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $761,784 | 684 | ABBVIE INC. ($158,067) |
| 2023 | $605,479 | 576 | Dermavant Sciences, Inc. ($135,958) |
| 2022 | $286,023 | 316 | ABBVIE INC. ($114,491) |
| 2021 | $182,420 | 226 | Janssen Scientific Affairs, LLC ($59,838) |
| 2020 | $168,250 | 248 | AbbVie Inc. ($71,638) |
| 2019 | $194,519 | 449 | Lilly USA, LLC ($67,386) |
| 2018 | $106,639 | 356 | Lilly USA, LLC ($86,512) |
| 2017 | $87,004 | 320 | Lilly USA, LLC ($58,375) |
All Payment Transactions
3,175 individual payment records from CMS Open Payments — Page 1 of 127
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $528.60 | General |
| Category: Inflammation | ||||||
| 12/27/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: DERMATOLOGY | ||||||
| 12/24/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,930.00 | General |
| Category: Inflammation | ||||||
| 12/24/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $342.73 | General |
| Category: Immunology | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $398.22 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $145.59 | General |
| Category: Inflammation | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | Cabtreo (Drug), JUBLIA | Food and Beverage | In-kind items and services | $22.49 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $28.93 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | PFIZER INC. | CIBINQO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,350.00 | General |
| Category: Inflammation & Immunology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $9.76 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: DERMATOLOGY | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,075.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,075.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/05/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $566.80 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $483.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $485.73 | General |
| Category: Immunology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $7,463 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,162 | 5,091 | $261,475 | $92,353 |
| 2022 | 18 | 1,411 | 7,814 | $332,208 | $119,379 |
| 2021 | 15 | 1,622 | 16,243 | $429,630 | $158,709 |
| 2020 | 13 | 734 | 5,776 | $167,795 | $55,769 |
Total Patients
4,929
Total Services
34,924
Medicare Billing
$426,209
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 248 | 360 | $58,320 | $22,822 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 183 | $42,822 | $17,220 | 40.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 214 | 319 | $45,298 | $12,694 | 28.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 139 | 168 | $36,456 | $11,644 | 31.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 69 | 85 | $20,570 | $7,377 | 35.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 173 | 776 | $10,088 | $4,117 | 40.8% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2023 | 15 | 3,000 | $12,000 | $3,896 | 32.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 76 | 83 | $8,217 | $3,412 | 41.5% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 15 | 15 | $8,550 | $3,253 | 38.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 38 | 55 | $6,380 | $2,201 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $7,476 | $1,870 | 25.0% |
| 10040 | Acne surgery | Office | 2023 | 12 | 14 | $3,318 | $1,304 | 39.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 12 | 12 | $1,980 | $543.15 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 270 | 434 | $70,308 | $28,443 | 40.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 197 | 247 | $53,599 | $18,436 | 34.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 238 | 372 | $52,824 | $14,992 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 134 | $31,356 | $12,896 | 41.1% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2022 | 24 | 5,000 | $20,000 | $6,308 | 31.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 201 | 1,156 | $15,028 | $6,249 | 41.6% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2022 | 24 | 25 | $14,250 | $5,689 | 39.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 46 | 54 | $13,068 | $4,603 | 35.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 70 | 96 | $11,136 | $4,062 | 36.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 75 | 96 | $9,504 | $3,807 | 40.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 20 | 25 | $8,525 | $3,132 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $9,256 | $2,875 | 31.1% |
About Dr. George Lewitt, M.D
Dr. George Lewitt, M.D is a Dermatology healthcare provider based in Northbrook, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2009. The National Provider Identifier (NPI) number assigned to this provider is 1902031313.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. George Lewitt, M.D has received a total of $2.4M in payments from pharmaceutical and medical device companies, with $761,784 received in 2024. These payments were reported across 3,175 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.8M).
As a Medicare-enrolled provider, Lewitt has provided services to 4,929 Medicare beneficiaries, totaling 34,924 services with total Medicare billing of $426,209. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Northbrook, IL
- Active Since 05/29/2009
- Last Updated 08/28/2013
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1902031313
Products in Payments
- TALTZ (Drug) $351,891
- TREMFYA (Drug) $336,355
- SKYRIZI (Biological) $303,234
- VTAMA (Drug) $250,308
- RINVOQ (Biological) $184,790
- Otezla (Drug) $158,944
- OLUMIANT (Drug) $97,104
- Bimzelx (Biological) $92,022
- Sotyktu (Drug) $68,351
- EPIDUO FORTE (Drug) $50,920
- Tremfya (Drug) $44,495
- Skyrizi (Biological) $37,997
- CIBINQO (Drug) $37,049
- AKLIEF (Drug) $33,950
- OPZELURA (Drug) $29,212
- TAPINAROF (Drug) $28,898
- Cimzia (Drug) $28,510
- HUMIRA (Biological) $28,220
- Zoryve (Drug) $23,807
- Humira (Biological) $17,834
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Northbrook
Jeffrey Draluck, M.d, M.D
Dermatology — Payments: $34,064
Dermatology $34,064
Bruce Bennin, M.d, M.D
Dermatology — Payments: $13,902
Dermatology $13,902
Dr. Kelly Park, M.d, M.D
Dermatology — Payments: $11,617
Dermatology $11,617
Renata Jenkin, Md, MD
Dermatology — Payments: $8,414
Dermatology $8,414
Dr. Andrew Scheman, M.d, M.D
Dermatology — Payments: $6,818
Dermatology $6,818
Dr. Nicole Huffman, M.d, M.D
Dermatology — Payments: $6,091
Dermatology $6,091